BayWas, Restructuring

BayWa's Restructuring Path Narrowed by Legal Woes and a Critical Asset Sale

13.04.2026 - 18:23:57 | boerse-global.de

German agri-trader BayWa races to sell T&G Global to plug a €2.7B funding gap after a key renewables deal collapsed, while facing legal probes and auditor disputes.

BayWa's Restructuring Path Narrowed by Legal Woes and a Critical Asset Sale - Foto: über boerse-global.de
BayWa's Restructuring Path Narrowed by Legal Woes and a Critical Asset Sale - Foto: über boerse-global.de

The German agricultural trading group BayWa is navigating a treacherous path through its financial restructuring, with its immediate fate tied to the sale of a key subsidiary and the forbearance of its creditors. The company's share price, down roughly 20% since the start of the year, reflects a market deeply skeptical of its ability to close a €2.7 billion funding gap.

Central to the current phase is the planned divestment of T&G Global, the New Zealand-based fruit trader in which BayWa holds a stake of nearly 74%. Investment bank Goldman Sachs was hired in March 2026 to manage the sale, which could yield approximately €300 million. T&G, known for apple brands like Envy and Jazz, reported a 2024 turnover of $1.3 billion and a net profit of $16 million, making it a viable asset. However, the process faces complications. Reports suggest the minority shareholder Joy Wing Mau Group from Hong Kong, with a stake of almost 20%, is creating obstacles. The company itself has stated no final decision has been made.

This sale is crucial because BayWa's original cornerstone restructuring plan—the €1.7 billion sale of a 51% stake in its renewable energy unit BayWa r.e.—collapsed in early 2025 following a shift in U.S. subsidy policy for renewable energy. The group's total refinancing need stands at €4 billion by 2028, of which only €1.3 billion has been secured.

A more immediate liquidity boost is expected by the end of April. The company anticipates a €45 million payment from the completed sale of its grain trading subsidiary Cefetra, supplemented by roughly €62 million from the repayment of shareholder loans. The deconsolidation of Cefetra is also projected to reduce group bank debt by more than €600 million, a key metric as BayWa seeks to extend its creditor standstill agreement.

Should investors sell immediately? Or is it worth buying BayWa?

The company's relationship with its auditors has shattered. PricewaterhouseCoopers (PwC), which issued an unqualified audit opinion for the 2023 accounts despite the company's subsequently revealed existential troubles, has been dismissed. BayWa is examining claims for damages against the auditor, with both German financial watchdog BaFin and the audit oversight body Apas conducting related proceedings. Ironically, PwC is still slated to audit the 2025 annual report, which is not expected until the fourth quarter of 2026 due to the pending revaluation of BayWa r.e.

This lack of audited figures leaves investors in the dark and coincides with mounting legal pressure. Law firm TILP is preparing a model case lawsuit, alleging BayWa AG is liable to shareholders who purchased stock between January 2022 and January 2026 based on incomplete capital market information. Separately, Munich prosecutors are investigating former CEOs Klaus Josef Lutz and Marcus Pöllinger on suspicion of breach of trust and the intentional misrepresentation of liquidity risks, with searches conducted in January. All accused are presumed innocent.

Internally, governance is being overhauled in response to the crisis. The supervisory board has lowered the approval threshold for transactions from €200 million to €50 million. Several board members have resigned in recent months, including Monika Hohlmeier and Michael Höllerer at the end of March, with Monique Surges set to follow at the end of May. From 2028, a new rotating election system will be introduced, with two members elected annually for a shortened four-year term.

BayWa at a turning point? This analysis reveals what investors need to know now.

With its 2026 forecast withdrawn and its adjusted EBITDA target for 2027 lowered to €140 million, BayWa's trajectory remains uncertain. The share price trades approximately 37% below its 52-week high of €21.50. Until the creditor standstill is extended into autumn 2026 and credible financial statements are published, the stock faces structural pressure, with its survival contingent on executing asset sales under the watchful eyes of banks and courts.

Ad

BayWa Stock: New Analysis - 13 April

Fresh BayWa information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BayWa analysis...

So schätzen die Börsenprofis BayWas Aktien ein!

<b>So schätzen die Börsenprofis BayWas Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
en | DE0005194005 | BAYWAS | boerse | 69139173 |